Viking Therapeutics, Inc. (VKTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
VKTX Stock Price Chart Interactive Chart >
VKTX Price/Volume Stats
|Current price||$6.69||52-week high||$10.09|
|Prev. close||$6.57||52-week low||$4.95|
|Day high||$6.91||Avg. volume||1,058,090|
|50-day MA||$6.13||Dividend yield||N/A|
|200-day MA||$6.36||Market Cap||523.09M|
Viking Therapeutics, Inc. (VKTX) Company Bio
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.
Most Popular Stories View All
VKTX Latest News Stream
|Loading, please wait...|
VKTX Latest Social Stream
View Full VKTX Social Stream
Latest VKTX News From Around the Web
Below are the latest news stories about Viking Therapeutics Inc that investors may wish to consider to help them evaluate VKTX as an investment opportunity.
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in four upcoming investor conferences.
If you want to know who really controls Viking Therapeutics, Inc. ( NASDAQ:VKTX ), then you'll have to look at the...
Joining me today is Brian Lian, Viking's president and CEO; and Greg Zante, Viking's CFO. Today, we'll provide an overview of our second-quarter 2021 financial results, as well as an update on recent progress and developments with our pipeline programs and operations.
Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2021, and provided an update on its clinical pipeline and other corporate developments.
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the second quarter 2021, after the market close on Wednesday, July 28, 2021.
VKTX Price Returns